Ispire to Participate in Benzinga Capital Conference in Florida

Events by 2FIRSTS.ai
Apr.10.2024
Ispire to Participate in Benzinga Capital Conference in Florida
Ispire to attend Benzinga Capital Conference in Florida, CEO Michael Wang to speak on product demand growth.

According to a report by PR Newswire on April 10th, Ispire (NASDAQ: ISPR) announced that the company will be participating in the Benzinga Capital Conference, taking place at the Diplomat Beach Resort in Hollywood, Florida on April 16th and 17th.

 

Co-CEO Michael Wang of the company will meet with investors on the morning of April 17, 2024, at 11:00 am Eastern Time in the United States, and will participate in a seminar titled "Puff to Profit: How a Sneaky Product Snuck up the Demand Rankings" and deliver a speech.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Lawmakers Push to Include E-Cigarettes in Vietnam’s Revised Investment Law Ban
Lawmakers Push to Include E-Cigarettes in Vietnam’s Revised Investment Law Ban
Vietnam’s National Assembly has debated amendments to the Investment Law that would include e-cigarettes, heated tobacco, and nitrous oxide (N₂O) in the list of prohibited business activities. Lawmakers supported a total ban consistent with WHO recommendations and previous National Assembly resolutions, citing rising youth addiction rates. Finance Minister Nguyễn Văn Thắng confirmed that the ban would apply comprehensively, with a short transition period for foreign factories.
Nov.27 by 2FIRSTS.ai
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
Philip Morris International Fails to Invalidate British American Tobacco Unit’s Vape Patent
The European Patent Office’s Board of Appeal upheld British American Tobacco’s Nicoventures Trading Ltd. vape patent, rejecting Philip Morris International’s objections. The board ruled that the patent’s use of predefined heater activation parameters not based on user puffs was novel and valid.
Nov.10
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
2Firsts Observations | Two Months After Launch, BAT’s VELO Shift Draws Attention for Non-Traditional Design as Some Users Call for Higher Nicotine Strength
British American Tobacco (BAT) introduced the VELO Shift nicotine pouch in September 2025, featuring a hexagonal outer can and an oval-triangle pouch shape that departs from traditional designs. Two months after launch, the product is available in the U.K., U.S. and Sweden. Social-media feedback indicates the design has been well received, while some users are calling for higher nicotine strength.
Nov.06 by 2FIRSTS.ai
AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
AIRSCREAM Solidifies South African Leadership & Championing Truth in Vaping
As South Africa’s leading lifestyle vaping brand, AIRSCREAM is accelerating its regional growth strategy with the launch of its bold new initiative, “Trust ML, Not Puff.” The campaign calls for factual, millilitre (ml)-based transparency across the vaping industry, directly confronting misleading puff-count marketing practices and promoting clear, standardised information that reflects the true value and capacity of vaping products.
Nov.28
COP11 Update: Deep Divide Over Regulation of E-cigarettes and Nicotine Pouches as EU Pushes Back Against "Total Ban" Draft
COP11 Update: Deep Divide Over Regulation of E-cigarettes and Nicotine Pouches as EU Pushes Back Against "Total Ban" Draft
At the ongoing COP11 in Geneva,a bloc led by Brazil and the Maldives has submitted a draft proposing "prohibition" as the primary policy path. In response, the European Union has submitted amendments requesting that the wording be adjusted to optional regulation, preserving the right of member states to decide on sales bans based on their own national laws.
Nov.21 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai